These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 9256890)

  • 1. Phase II trial with BCNU plus alpha-interferon in patients with recurrent high-grade gliomas.
    Brandes AA; Scelzi E; Zampieri P; Rigon A; Rotilio A; Amista P; Berti F; Fiorentino MV
    Am J Clin Oncol; 1997 Aug; 20(4):364-7. PubMed ID: 9256890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I evaluation of radiation combined with recombinant interferon alpha-2a and BCNU for patients with high-grade glioma.
    Rajkumar SV; Buckner JC; Schomberg PJ; Cascino TL; Burch PA; Dinapoli RP
    Int J Radiat Oncol Biol Phys; 1998 Jan; 40(2):297-302. PubMed ID: 9457812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase III study of radiation therapy plus carmustine with or without recombinant interferon-alpha in the treatment of patients with newly diagnosed high-grade glioma.
    Buckner JC; Schomberg PJ; McGinnis WL; Cascino TL; Scheithauer BW; O'Fallon JR; Morton RF; Kuross SA; Mailliard JA; Hatfield AK; Cole JT; Steen PD; Bernath AM
    Cancer; 2001 Jul; 92(2):420-33. PubMed ID: 11466698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carboplatin and teniposide concurrent with radiotherapy in patients with glioblastoma multiforme: a phase II study.
    Brandes AA; Rigon A; Zampieri P; Ermani M; Carollo C; Altavilla G; Turazzi S; Chierichetti F; Florentino MV
    Cancer; 1998 Jan; 82(2):355-61. PubMed ID: 9445194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II evaluation of recombinant interferon alpha and BCNU in recurrent glioma.
    Buckner JC; Brown LD; Kugler JW; Cascino TL; Krook JE; Mailliard JA; Kardinal CG; Tschetter LK; O'Fallon JR; Scheithauer BW
    J Neurosurg; 1995 Mar; 82(3):430-5. PubMed ID: 7861221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicenter phase I/II study of the BCNU implant (Gliadel(®) Wafer) for Japanese patients with malignant gliomas.
    Aoki T; Nishikawa R; Sugiyama K; Nonoguchi N; Kawabata N; Mishima K; Adachi J; Kurisu K; Yamasaki F; Tominaga T; Kumabe T; Ueki K; Higuchi F; Yamamoto T; Ishikawa E; Takeshima H; Yamashita S; Arita K; Hirano H; Yamada S; Matsutani M;
    Neurol Med Chir (Tokyo); 2014; 54(4):290-301. PubMed ID: 24739422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I evaluation of preirradiation chemotherapy with carmustine and cisplatin and accelerated radiation therapy in patients with high-grade gliomas.
    Rajkumar SV; Buckner JC; Schomberg PJ; Pitot HC; Ingle JN; Cascino TL
    Neurosurgery; 1999 Jan; 44(1):67-73. PubMed ID: 9894965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early chemotherapy and concurrent radio-chemotherapy in high grade glioma.
    Brandes AA; Rigon A; Zampieri P; Scelzi E; Amistà P; Berti F; Rotilio A; Gardiman M; Fiorentino MV
    J Neurooncol; 1996 Dec; 30(3):247-55. PubMed ID: 8943100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of newly diagnosed glioblastoma multiforme with carmustine, cisplatin and etoposide followed by radiotherapy. A phase II study.
    Lassen U; Kristjansen PE; Wagner A; Kosteljanetz M; Poulsen HS
    J Neurooncol; 1999 Jun; 43(2):161-6. PubMed ID: 10533728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiation therapy and hydroxyurea followed by the combination of 6-thioguanine and BCNU for the treatment of primary malignant brain tumors.
    Prados MD; Larson DA; Lamborn K; McDermott MW; Sneed PK; Wara WM; Chang SM; Mack EE; Krouwer HG; Chandler KL; Warnick RE; Davis RL; Rabbitt JE; Malec M; Levin VA; Gutin PH; Phillips TL; Wilson CB
    Int J Radiat Oncol Biol Phys; 1998 Jan; 40(1):57-63. PubMed ID: 9422558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase III trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group 9503 Trials.
    Buckner JC; Ballman KV; Michalak JC; Burton GV; Cascino TL; Schomberg PJ; Hawkins RB; Scheithauer BW; Sandler HM; Marks RS; O'Fallon JR; ;
    J Clin Oncol; 2006 Aug; 24(24):3871-9. PubMed ID: 16921039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical course and pathologic findings after Gliadel and radiotherapy for newly diagnosed malignant glioma: implications for patient management.
    Kleinberg LR; Weingart J; Burger P; Carson K; Grossman SA; Li K; Olivi A; Wharam MD; Brem H
    Cancer Invest; 2004; 22(1):1-9. PubMed ID: 15069758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advantages and Disadvantages of Combined Chemotherapy with Carmustine Wafer and Bevacizumab in Patients with Newly Diagnosed Glioblastoma: A Single-Institutional Experience.
    Akiyama Y; Kimura Y; Enatsu R; Mikami T; Wanibuchi M; Mikuni N
    World Neurosurg; 2018 May; 113():e508-e514. PubMed ID: 29476996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I and pharmacokinetic study of preirradiation chemotherapy with BCNU, cisplatin, etoposide, and accelerated radiation therapy in patients with high-grade glioma.
    Rajkumar SV; Buckner JC; Schomberg PJ; Reid JM; Bagniewski PJ; Ames MM; Cascino TL; Marks RS
    Int J Radiat Oncol Biol Phys; 1998 Dec; 42(5):969-75. PubMed ID: 9869217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: a New Approaches to Brain Tumor Therapy CNS Consortium trial.
    Olivi A; Grossman SA; Tatter S; Barker F; Judy K; Olsen J; Bruce J; Hilt D; Fisher J; Piantadosi S;
    J Clin Oncol; 2003 May; 21(9):1845-9. PubMed ID: 12721262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incorporating BCNU wafers into malignant glioma treatment: European case studies.
    Balossier A; Dörner L; Emery E; Heese O; Mehdorn HM; Menei P; Singh J
    Clin Drug Investig; 2010; 30(3):195-204. PubMed ID: 20155992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The safety of interstitial chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: phase I trial.
    Brem H; Ewend MG; Piantadosi S; Greenhoot J; Burger PC; Sisti M
    J Neurooncol; 1995 Nov; 26(2):111-23. PubMed ID: 8787853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
    Brandes AA; Tosoni A; Basso U; Reni M; Valduga F; Monfardini S; Amistà P; Nicolardi L; Sotti G; Ermani M
    J Clin Oncol; 2004 Dec; 22(23):4779-86. PubMed ID: 15570079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of recurrent gliomas with 1,3-bis(2-chloroethyl)-1-nitrosourea and alpha-difluoromethylornithine.
    Prados M; Rodriguez L; Chamberlain M; Silver P; Levin V
    Neurosurgery; 1989 Jun; 24(6):806-9. PubMed ID: 2546093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
    Raizer JJ; Malkin MG; Kleber M; Abrey LE
    Neuro Oncol; 2004 Jul; 6(3):247-52. PubMed ID: 15279717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.